Matsumoto T, Tsuda S, Nakamura S
Drug Discovery Research Laboratories, Hiroshima University School of Medicine, Japan.
J Neural Transm Gen Sect. 1995;100(1):1-15. doi: 10.1007/BF01276861.
The neurotrophic effects of ebiratide, an ACTH4-9 analog, have been examined using both fetal rat septal cultures and aged rats. The 5-day treatment with ebiratide (10-100 pmol/ml) partially prevented neuronal degeneration that occurred in the cultures in which cells were sparsely plated. Ebiratide (10 pmol/ ml) increased choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activities up to 1.5 and 1.2 times the respective control values in the sub-confluent cultures. AChE cytochemistry of the cultures has shown that ebiratide increased the stained area per cell. Ebiratide subcutaneously administered by constant infusion (10 nmol/body/hr) for 4 weeks elevated ChAT activities in the septum (35% over control), neocortex (79%) and hippocampus (89%) of aged rats. Thus, the present study indicates that ebiratide shares neurotrophic properties which may prove beneficial in the therapy for CNS degenerative disorders, especially Alzheimer's disease.
已使用胎鼠中隔培养物和老年大鼠研究了促肾上腺皮质激素4-9类似物埃比拉肽的神经营养作用。用埃比拉肽（10-100 pmol/ml）进行5天治疗可部分预防在细胞稀疏接种的培养物中发生的神经元变性。在亚汇合培养物中，埃比拉肽（10 pmol/ml）使胆碱乙酰转移酶（ChAT）和乙酰胆碱酯酶（AChE）活性分别提高至各自对照值的1.5倍和1.2倍。培养物的AChE细胞化学显示，埃比拉肽增加了每个细胞的染色面积。通过持续输注（10 nmol/体/小时）皮下给予埃比拉肽4周，可提高老年大鼠中隔（比对照高35%）、新皮质（79%）和海马体（89%）中的ChAT活性。因此，本研究表明，埃比拉肽具有神经营养特性，这可能在中枢神经系统退行性疾病，尤其是阿尔茨海默病的治疗中证明是有益的。
